# Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

> **NCT03454503** · — · COMPLETED · sponsor: **Hikma Pharmaceuticals LLC** · enrollment: 173 (actual)

## Conditions studied

- Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT03454503
- **Lead sponsor:** Hikma Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-13
- **Primary completion:** 2020-12-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454503, "Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03454503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*